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Structured Abstract
Purpose—Little is known about pregnancy attempts among female young cancer survivors 
(YCS). We sought to determine fertility preservation (FP), demographic, cancer and reproductive 
characteristics associated with pregnancy attempts after cancer.
Methods—We recruited 251 female YCS (ages 18-44) to complete a survey on reproductive 
health outcomes. We used log-binomial regression models to estimate relative risks (RR) for 
characteristics associated with pregnancy attempts.
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Results—For the entire cohort, median time since cancer diagnosis was 2.4 years (interquartile 
range 4.0). Fifty-two YCS (21%) attempted pregnancy after cancer diagnosis. In unadjusted 
analyses, lack of FP therapy prior to cancer treatment, older age, partnered relationship, higher 
income, history of stem cell or bone marrow transplant, and longer duration of survivorship were 
significantly associated with pregnancy attempts. In multivariable analyses, YCS who did not 
undergo FP therapy were more than twice as likely to attempt pregnancy as those who did undergo 
FP therapy (RR 2.4, 95%CI 1.3, 4.3). Partnered status (RR 7.1, 95%CI 2.5, 20.2) and >2 years 
since cancer diagnosis (RR 2.3, 95%CI 1.3, 4.1) were also significantly associated with attempts.
Conclusions—In YCS, milestones including partnered relationships and longer duration of 
cancer survivorship are important to attempting pregnancy. A novel, inverse association between 
FP therapy and pregnancy attempts warrants further study.
Implications for Cancer Survivors—Pregnancy attempts after cancer were more likely after 
attaining both social and cancer-related milestones. As these milestones require time, YCS should 
be made aware of their potential for concomitant, premature loss of fertility in order to preserve 
their range of fertility options.
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Introduction
Over 380,000 female adolescent and young adult cancer survivors live in the United States 
[1]. Because of improved long-term survival, young adult-aged cancer survivors (YCS) 
expect to raise their own families and prefer biologic children over adoption and third party 
reproduction [2,3]. The decision to attempt pregnancy for any young adult is complex. 
Young adults are often at a pivotal stage of their life development, in terms of pursuing 
educational and career goals, financial stability, and committed romantic relationships [4–7]. 
With prior cancer and cancer treatment, YCS face not only these psychosocial factors, but 
also uncertainty on cancer status, higher risks of chronic medical conditions, potential for 
impaired fecundity and premature ovarian aging, all of which may affect the decision to 
attempt pregnancy [8–15].
Little is known about what influences the decision to attempt pregnancy after cancer. 
Oncology, reproductive medicine and pediatric professional societies recommend that health 
care providers discuss with reproductive-aged patients the potential threats that cancer and 
cancer treatments pose to future fertility, and refer for fertility preservation (FP) counseling 
and treatments as indicated [16–18]. Whether FP counseling and therapy impacts pregnancy 
attempts after cancer is not known. Because many female YCS face a narrowed reproductive 
window, it is necessary to identify factors that drive the decision to attempt pregnancy to 
understand how to best support their reproductive goals. Therefore, the objective of this 
study was to examine the association between pregnancy attempts in YCS and prior fertility 
preservation, demographic, cancer history, and reproductive characteristics.
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Participants were female YCS who were recruited to the Fertility Information Research 
Study (FIRST), an ongoing prospective cohort study of reproductive health outcomes after 
cancer. Participants were recruited through social media outreach by cancer advocacy 
groups and six university-based FP programs [19]. Eligible individuals were consented over 
the telephone and completed the study questionnaire via either telephone interview or the 
Internet. To be eligible for FIRST, participants must be female, aged 18 to 44 at study 
enrollment, and have a personal history of cancer or cancer treatment. Participants represent 
variable durations since cancer diagnosis. Participants who underwent a hysterectomy and/or 
bilateral oophorectomy were excluded from the current analysis. This study was approved 
by the institutional review board at the University of California, San Diego.
Questionnaire data
Demographics, cancer and treatment characteristics, medical conditions, and reproductive 
health questions were included in the study questionnaire completed by participants at the 
time of recruitment. Demographic data included: age at study enrollment, race/ethnicity, 
relationship status, education, and annual household income. Additionally, questions were 
asked to assess self-reported health habits (e.g., smoking status), body mass index (BMI) 
and current medical conditions (e.g., asthma, diabetes, depression). Participants reported 
information about cancer type and stage, cancer treatments (e.g., radiation, surgery, 
chemotherapy), cancer recurrence, and year of cancer diagnosis. Regarding reproductive 
health, participants reported on history of hysterectomy and/or oophorectomy, menstrual 
cycle pattern, pregnancy, and infertility using questions derived from the National Survey of 
Family Growth [20], the Penn Ovarian Aging Study [21] and the Olsen time to pregnancy 
questionnaire [22].
Participants completed questions assessing their experience with FP prior to their cancer 
treatment. To assess FP referral, women were asked, “Before your cancer treatment began, 
were you and/or your family ever referred to a fertility specialist to talk about fertility 
preservation?” To assess use of FP therapy, women answered the following questions: 1) 
“Have you ever used any therapies or interventions to preserve your fertility?” and 2) “What 
therapies or medical interventions have you used to preserve your fertility?” The answer 
choices for the latter question were embryo banking, egg banking, ovarian tissue banking, 
ovarian suppression with medication, ovarian shielding during radiation, ovarian 
transposition, conservative gynecologic surgery, or other.
Pregnancy Attempt after Cancer—Women were classified as having attempted 
pregnancy after cancer based on a series of questions ascertaining pregnancy, attempted 
pregnancy, and history of infertility that occurred after the date of cancer diagnosis. First, 
participants were asked, “Are you trying to become pregnant now?” Those who answered 
yes were classified as attempting pregnancy. Next, participants were asked, “Have you ever 
tried to become pregnant for at least a year without becoming pregnant?” Participants who 
answered yes were asked to provide the date when they first started trying to get pregnant. 
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Those participants who provided a date after their cancer diagnosis date were classified as 
attempting pregnancy after cancer. Lastly, women were asked, “Have you ever been 
pregnant?” Of those who responded in the affirmative, the date of the end of their 
pregnancy, length of gestation and time to pregnancy were ascertained, from which the start 
of their pregnancy attempts after cancer diagnosis could be calculated. Women with a 
pregnancy attempt start date after their cancer diagnosis date were classified as having 
attempted pregnancy after cancer.
Statistical Methods
Descriptive statistics were calculated as frequencies and percentages for categorical data and 
median and interquartile ranges (IQR) for continuous data. The primary exposure of interest 
was FP therapy prior to cancer treatment. Participants who answered yes to using any FP 
therapy were classified as having undergone fertility preservation. The primary outcome was 
attempting pregnancy after cancer diagnosis.
In order to identify factors associated with pregnancy attempts after cancer diagnosis, 
bivariable analyses were conducted. Factors considered in these analyses included 
participant demographics (e.g., age at study enrollment, race, education, income, 
relationship status), cancer and treatment characteristics (e.g., cancer type, stage, time since 
cancer diagnosis, treatment type), and fertility preservation characteristics (e.g., FP referral, 
FP therapy). Analysis was performed using Fisher's Exact, Chi-square or Student's t-test, as 
appropriate. Time since cancer diagnosis was dichotomized into ≤2 years and >2 years 
based on the common recommendation to defer pregnancy for at least 2 years post-cancer 
diagnosis. Comorbid medical conditions were categorized as 0 conditions versus 1 or more 
conditions, and cancer treatments received were dichotomized as yes versus no. For 
example, receipt of any kind of chemotherapy was classified as yes or no.
Log-binomial regression models were used to estimate relative risks (RR) for characteristics 
associated with pregnancy attempts after cancer diagnosis. FP therapy (the primary exposure 
of interest) along with variables associated with pregnancy attempts at p<0.05 in the 
bivariable analyses were included in the final adjusted regression model. Significance for all 
analyses was set at p<0.05. All analyses were conducted using SAS statistical software v9.3 
(Cary, NC).
Results
A total of 295 participants completed the study questionnaire between May 2011 and 
February 2013. For the current analysis, 251 participants were included, while 26 
participants were excluded due to prior hysterectomy and/or bilateral oophorectomy, and 18 
participants were excluded due to missing data on the main study outcome (pregnancy 
attempt after cancer diagnosis).
Table 1 depicts baseline characteristics of participants. The mean age at study enrollment 
(standard deviation [SD]) of the participants was 31.3 (5.6) years, and the median time since 
cancer diagnosis (interquartile range) was 2.4 (4.0) years. The majority of participants were 
white (79%), college graduates (86%), in a partnered relationship (57%), and endorsed the 
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desire to have a baby in the future (88%). The two most common cancer types were breast 
cancer (32%) and lymphoma (28%). Approximately 81% of participants received 
chemotherapy, and 51% received radiation therapy. For FP characteristics, 45% of 
participants received a referral to a fertility specialist for a consultation, and 35% underwent 
FP therapy prior to their cancer treatment. Specifically, 24% underwent embryo or oocyte 
cryopreservation.
Fifty-two YCS (21%) attempted pregnancy after cancer diagnosis. Among these YCS, 7 
women (13%) had their first pregnancy attempt < 1 year, 11 women (21%) at 1-2 years, 11 
women (21%) at 2-3 years, 6 women (12%) at 3-4 years, and 17 women (33%) > 4 years 
after cancer diagnosis. Twenty-seven women conceived after their first pregnancy attempt, 
of which 17 achieved live births. Of the remaining 10 pregnancies, there were 5 spontaneous 
abortions, 2 elective terminations, 1 tubal pregnancy, and 2 ongoing pregnancies. Twenty-
three of the 52 YCS are currently continuing to attempt pregnancy. Two women were 
diagnosed with infertility and are no longer attempting pregnancy.
In unadjusted analyses, older age, partnered relationship status, income > $50K, and longer 
duration of cancer survivorship were significantly associated with pregnancy attempts 
(Table 1). None of the 15 participants who underwent prior stem cell or bone marrow 
transplants attempted pregnancy (p=0.05). Cancer diagnosis, stage and treatment, age at 
cancer diagnosis as well as comorbid medical conditions were not associated with 
pregnancy attempts.
Among fertility preservation variables, referral to FP counseling prior to cancer treatment 
was not associated with pregnancy attempts after cancer treatment (p=0.35) (Figure 1). 
However, participants who did not undergo FP therapy were more likely to attempt 
pregnancy compared to participants who had undergone FP therapy prior to cancer treatment 
(26% vs. 11%, p=0.008). Similarly, participants who did not undergo embryo or oocyte 
cryopreservation were more likely to attempt pregnancy compared to participants who 
banked embryos or oocytes (25% vs. 8%, p=0.006). Compared to participants who 
underwent FP therapy, those who did not undergo FP therapy were more likely to self-report 
as white or Asian than black (p=0.01), were more likely to have had a live birth before 
cancer diagnosis (p=0.03), and were more likely to undergo radiation therapy than not 
undergo radiation therapy (p=0.03). While YCS with thyroid cancer were less likely to 
undergo FP therapy (p=0.005), FP therapy was not associated with other cancer types. Age 
at diagnosis, additional demographic and reproductive characteristics, cancer stage, and 
receipt of cancer treatment other than radiation therapy (i.e., surgery, chemotherapy, 
endocrine therapy and bone marrow or stem cell transplant) were not associated with FP 
therapy (data not shown).
Estimates from multivariable modeling of pregnancy attempts after cancer are shown in 
Table 2. In a model adjusting for age at study enrollment, relationship status, income, and 
survivorship duration, YCS who did not undergo FP therapy were more than twice as likely 
to attempt pregnancy as women who underwent FP therapy [RR 2.4, 95% Confidence 
Interval (CI) 1.3, 4.3]. Women who were in a partnered relationship status were seven times 
more likely to attempt pregnancy than those who were not partnered (RR 7.1, 95%CI 2.5, 
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20.2). Women who were at least 2 years post-cancer diagnosis were twice as likely to 
attempt pregnancy compared to women within 2 years of their cancer diagnosis (RR 2.3, 
95%CI 1.3, 4.1). In this model, age and income were no longer significantly associated with 
pregnancy attempts. Further, when restricting the type of FP therapy to embryo and/or 
oocyte cryopreservation, women who did not undergo these FP procedures were 3 times 
more likely to attempt pregnancy than women who underwent embryo/oocyte 
cryopreservation (RR 3.0, 95% CI 1.3, 6.8).
Discussion
In this contemporary cohort of young female cancer survivors, partnered relationships and 
longer duration of cancer survivorship were significantly associated with pregnancy 
attempts. Conversely, young women who underwent fertility preservation therapy prior to 
cancer treatment were less likely to attempt pregnancy. The decision to attempt pregnancy 
after cancer appears to involve achieving both social and cancer-related milestones. As these 
milestones require time, YCS should be made aware of their potential for concomitant, 
premature loss of fertility in order to preserve their range of fertility options.
The finding that YCS who underwent FP therapy were less likely to attempt pregnancy after 
cancer is novel and may have important clinical implications. While further research is 
needed to explore why those who underwent FP therapy were less likely attempt pregnancy 
after cancer, it is possible that YCS who underwent FP therapy feel that they have preserved 
their fertility potential and hence defer childbearing to pursue other life goals, such as 
education, career, and financial stability. This would be of concern if YCS have 
misperceptions related to FP therapy and the success of assisted reproduction via embryo or 
oocyte freezing. Among cancer survivors, Balthazar and colleagues (2012) reported that FP 
knowledge after a single FP counseling visit was poor, with the median knowledge score 
about FP equal to 6 out of 13 possible points [23]. Since the average age-dependent 
percentages of thawed embryo transfer cycles resulting in live births range from 17% to 
39% in the U.S. [24], YCS need to be adequately educated about their future reproductive 
potential derived from FP therapy.
Young adult cancer survivors and healthy young adults have some similarities and 
differences regarding timing of childbearing. We found that YCS who were in a partnered 
relationship were significantly more likely to attempt pregnancy after cancer, which is 
consistent with data from healthy women [25,26] and a smaller cohort of YCS [27]. In 
addition to a partnered relationship, studies have shown that in young healthy women, 
education, financial stability and age have been shown to be highly influential on the timing 
of childbearing [28–32]. However among YCS in this study, age, education, and income 
were not significant factors influencing pregnancy attempts in the adjusted model. Since 
YCS experience considerable developmental and life course interruptions as a result of their 
cancer experience, it is possible that these milestones are less important to YCS than to 
healthy women [14,33,34]. Alternatively, it is also possible that the relative homogeneity in 
age, education and income of this cohort limited our power to detect independent 
associations with our outcome of interest.
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We found that longer duration of cancer survivorship was significantly associated with 
attempting pregnancy. Women who were at least 2 years post-cancer diagnosis were more 
likely to have attempted pregnancy than those diagnosed more recently. This finding may be 
due to the common physician recommendation for cancer patients to wait at least 2 years 
post-diagnosis before attempting pregnancy. It should be noted that this recommendation is 
generally considered for breast cancer patients with estrogen-sensitive tumors for several 
reasons: 1) higher risk of recurrence within 2 years after the initial diagnosis [35,36] and 2) 
benefit of endocrine therapy on survival outcomes [37,38]. However, Azim and colleagues 
(2013) found no difference in disease-free survival among breast cancer patients who 
became pregnant within 2 years of diagnosis and those who became pregnant after 2 years 
[39]. Additionally, cohort studies generally show that pregnancy after breast cancer is not 
associated with adverse cancer outcomes [39–42]. In a meta-analysis, investigators found a 
41% reduced risk of death in women who became pregnant after breast cancer compared to 
those who did not [40]. These findings can inform decisions on attempting pregnancy, 
particularly after breast cancer. Thus, updated knowledge about the risks associated with 
pregnancy after breast cancer should be communicated to YCS and their health care 
providers.
Among remaining cancer and treatment characteristics, only history of bone marrow or stem 
cell transplant was associated with a lower rate of pregnancy attempt. Because conditioning 
treatments that precede transplant confer severe gonadotoxicity, it is possible that these YCS 
did not attempt pregnancy because they experienced ovarian failure. Indeed, 5/15 (33.3%) 
reported no periods over the prior 12 months, while 9/15 (60.0%) reported being on birth 
control pills or menopausal hormone therapy. Although these numbers were very low, this is 
an interesting finding that warrants further research. We anticipated a healthy survivor bias, 
i.e. more pregnancy attempts in women with better prognosis. This was not observed, 
possibly because we recruited an ambulatory population with few participants with 
metastatic disease (n=18) and significant co-morbidities. It is likely that the study was 
underpowered to detect an association between health status and pregnancy attempts.
Modest rates of fertility preservation consultation and treatments were reported by 
participants of this study. The National Comprehensive Cancer Network (NCCN) adolescent 
and young adult clinical practice guidelines [14] and the American Society of Clinical 
Oncology (ASCO) guidelines [16] support FP discussions in reproductive-aged cancer 
patients. Our study findings showed that 45% received a FP consultation referral and 35% 
(66% of those who received an FP referral) underwent FP treatments. Other studies have 
found similar rates of FP therapy among YCS [43,44]. Kim and colleagues (2012) reported 
data from three fertility preservation centers showing 58% of breast cancer patients who 
underwent a FP consultation subsequently completed FP therapy. In contrast, some studies 
have shown much lower rates of FP use [45,46]. For example, among 981 female YCS 
recruited from the California Cancer Registry, only 4% pursued FP treatments [46]. Also 
Partridge and colleagues (2008) reported that 56% of the young breast cancer survivors in 
their study desired a future pregnancy at cancer diagnosis, yet only 10% underwent FP 
therapy [45]. This discrepancy in rates of FP therapy may be due to an increased awareness 
of fertility preservation in the past few years. Higher rates in recent studies may also be due 
to access to reproductive specialists. For example, our study recruited more recently 
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diagnosed participants from university-based FP programs; whereas, Letourneau and 
colleagues recruited participants diagnosed between 1993 and 2007 from the California 
Cancer Registry [46]. Overall, these findings suggest increasing exposure to FP counseling 
and therapy, but many reproductive-aged patients are still lacking access to FP care prior to 
their cancer treatment.
The strengths of this study are the large cohort size of female reproductive-aged YCS, 
diversity of cancer types and stages, and comprehensive data collection on cancer and 
treatment characteristics and reproductive health outcomes (e.g., pregnancy, infertility, FP 
therapy), which allowed us to consider a large number of important covariates and potential 
confounding factors. Our cohort of YCS primarily diagnosed within the past 5 years allowed 
us to examine current FP practices and pregnancy attempts. It should be noted that the use of 
social media outreach to recruit participants was successful at reaching a geographically 
diverse sample of YCS. While this study provides needed insight into the complex factors 
associated with pregnancy attempts after cancer, it also raises additional unanswered 
questions related to fertility outcomes for YCS, such as prospectively determining factors 
that influence pregnancy attempts, how to intervene on patients and providers to improve 
access and use of FP, and the use of banked embryos or oocytes to achieve pregnancy.
Several limitations to the study should be noted. The primary limitation is the reliance on 
self-report for the study variables, which may result in misclassification. For example, the 
definition of our main study outcome was based on 3 self-report questions. Some women 
may have been attempting pregnancy after their cancer diagnosis yet failed to respond 
affirmatively to any of the 3 questions chosen to define a pregnancy attempt and were 
therefore not classified as attempting pregnancy. Conversely, some women may have 
unintentionally become pregnant after their cancer diagnosis, yet were classified as 
attempting pregnancy based on an affirmative response to having ever been pregnant after 
their cancer diagnosis. In addition, we did not ascertain information on whether participants 
sought or received medical clearance for pregnancy, which may impact the timing of 
pregnancy attempts. However, in an ongoing follow up of this cohort with data on 231 
participants to date, nearly half (45%) report that they have received no recommendations on 
timing of pregnancy from a medical provider. We will explore this in future analyses of our 
longitudinal data. Our study findings are based on cross-sectional data collected at study 
enrollment, resulting in our inability to comment on causative relationships. Another 
limitation is that participants were recruited from FP programs and social media and elected 
to participate in a study about fertility and cancer, possibly indicating a heightened interest 
in future fertility to be noted when considering the generalizability of the study. Additional 
generalizability concerns include that most participants were white, well educated, reported 
a yearly income > $50,000, and were within 5 years of cancer diagnosis.
This is the first study to examine factors associated with pregnancy attempts among young 
adult female cancer survivors. For this population, factors such as being in a stable 
relationship and duration of cancer survivorship are critical to decisions regarding pregnancy 
attempts, but take time to achieve. As accelerated ovarian aging occurs concurrent to known 
delays in reaching these milestones, awareness of the impact of these competing factors on 
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fertility must be raised in YCS. The new finding of an inverse association between FP 
therapy and pregnancy attempts warrants further study.
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Fig. 1. Proportions of participants attempting pregnancy by fertility preservation (FP) 
characteristics (N=251)
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Table 1
Participant characteristics by attempting pregnancy after cancer in a cohort of female 
adolescent and young adult survivors (N=251)
Participant Characteristics
Overall Pregnancy Attempt N=52 No Pregnancy Attempt N=199
P valuea
N (%) N (%) N (%)
Demographics
Age at Study Enrollment, years <0.01
 Mean [SD] 31.3 [5.6] 33.8 [4.7] 30.6 [5.6]
 19 to 25 47 (18.8) 3 (5.8) 44 (22.2)
 26 to 31 86 (34.4) 14 (26.9) 72 (36.4)
 32 to 37 85 (34.0) 25 (48.1) 60 (30.3)
 38 to 44 32 (12.8) 10 (19.2) 22 (11.1)
Race 0.63
 White 198 (79.2) 39 (75.0) 159 (80.3)
 Black 8 (3.2) 1 (1.9) 7 (3.5)
 Asian 13 (5.2) 3 (5.8) 10 (5.1)
 Other 31 (12.4) 9 (17.3) 22 (11.1)
Body Mass Index (kg/m2) 0.59
 < 25 146 (58.2) 27 (51.9) 119 (59.8)
 25 – 29.9 58 (23.1) 14 (26.9) 44 (22.1)
 ≥ 30 47 (18.7) 11 (21.2) 36 (18.1)
Education 0.82
 College graduate 214 (86.3) 46 (88.5) 168 (85.7)
 Did not graduate from college 34 (13.7) 6 (11.5) 28 (14.3)
Income <0.01
 ≤ $50,000 80 (31.9) 6 (11.5) 74 (37.2)
 > $50,000 120 (47.8) 37 (71.2) 83 (41.7)
 Declined to answer 51 (20.3) 9 (17.3) 42 (21.1)
Current Smoker 6 (2.4) 2 (3.9) 4 (2.0) 0.61
Comorbid Medical Conditionsb 1.00
 0 89 (35.5) 18 (34.6) 71 (35.7)
 1 or more 162 (64.5) 34 (65.4) 128 (64.3)
Reproductive Characteristics
Relationship Status <0.01
 Partnered 143 (57.0) 48 (92.3) 95 (47.7)
 Not partnered 108 (43.0) 4 (7.7) 104 (52.3)
Live Birth Before Cancer Diagnosis 41 (16.3) 12 (23.1) 29 (14.6) 0.15
Desire to Have a Baby in the Future 220 (87.6) 43 (91.5) 177 (100.0) <0.01
Cancer & Treatment Characteristics
Cancer Diagnosis 0.21
 Breast 81 (32.3) 17 (32.7) 64 (32.2)
 Lymphoma 69 (27.5) 12 (23.1) 57 (28.7)






















Dominick et al. Page 14
Participant Characteristics
Overall Pregnancy Attempt N=52 No Pregnancy Attempt N=199
P valuea
N (%) N (%) N (%)
 Blood/Leukemia 19 (7.6) 4 (7.7) 15 (7.5)
 Thyroid 14 (5.5) 7 (13.5) 7 (3.5)
 Gynecologic (cervix/uterus/ovary) 13 (5.2) 2 (3.8) 11 (5.5)
 Other 55 (21.9) 10 (19.2) 45 (22.6)
Cancer Stage 0.16
 I 53 (21.5) 11 (21.6) 42 (21.5)
 II 76 (30.9) 17 (33.3) 59 (30.3)
 III 45 (18.3) 6 (11.7) 39 (20.0)
 IV 18 (7.3) 1 (2.0) 17 (8.7)
 Unknown 54 (22.0) 16 (31.4) 38 (19.5)
Time Since Cancer Diagnosis <0.01
 Median [IQR], years 2.4 [4.0] 5.0 [7.1] 2.1 [3.3]
 ≤ 2 years 108 (43.0) 11 (21.2) 97 (48.7)
 > 2 years 143 (57.0) 41 (78.8) 102 (51.3)
Surgery 151 (60.2) 35 (67.3) 116 (58.3) 0.27
Chemotherapy 204 (81.3) 38 (73.1) 166 (83.4) 0.11
Radiation Therapy 127 (50.6) 28 (53.9) 99 (49.8) 0.64
Endocrine Therapy 48 (19.1) 11 (21.2) 37 (18.6) 0.69
Bone Marrow or Stem Cell Transplant 15 (6.0) 0 (0.0) 15 (7.5) 0.05
Note: Due to missing data, some variables do not add up to 251.
a
Fisher's exact tests were used for categorical variables, and Student's t-tests were performed for continuous variables.
b
Comorbid medical conditions included asthma/lung disease, high blood pressure, diabetes/high blood sugar, being overweight (obesity), 
overactive/underactive thyroid, depression/bipolar disorder, eating disorder, rheumatologic diseases, Crohn's disease/ulcerative colitis, seizures/
neurologic disorders, TIA/stroke.
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